Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tissue growth

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    614 result(s) found for: Tissue growth. Displaying page 1 of 31.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-002992-17 Sponsor Protocol Number: A6281271 Start Date*: 2015-05-14
    Sponsor Name:Pfizer, Inc.
    Full Title: EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM®
    Medical condition: Growth retardation related to long-term glucocorticoid therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10053759 Growth retardation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000231-27 Sponsor Protocol Number: NN8640-4263 Start Date*: 2019-04-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Trial now transitioned) DK (Completed) AT (Ongoing) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Ongoing) IE (Completed) EE (Completed) LV (Trial now transitioned) PL (Trial now transitioned) HU (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000531-32 Sponsor Protocol Number: NN8640-4172 Start Date*: 2015-12-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, multinational, active-controlled,(open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared...
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) SI (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002974-28 Sponsor Protocol Number: NN8640-4468 Start Date*: 2023-07-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of once weekly dosing of somapacitan with daily Norditropin® in Chinese children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000647-14 Sponsor Protocol Number: 15782601 Start Date*: 2016-05-23
    Sponsor Name:University Hospital Toulouse
    Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial
    Medical condition: Noonan syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005743-24 Sponsor Protocol Number: 1214 Start Date*: 2013-07-23
    Sponsor Name:Centre Oscar Lambret
    Full Title: ACTIVITY AND SAFETY OF REGORAFENIB IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA PREVIOUSLY TREATED WITH ANTHRACYCLIN-BASED CHEMOTHERAPY: A MULTINATIONAL, RANDOMIZED, PHASE II, PLACEBO-CONTROLLED...
    Medical condition: Metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001467-23 Sponsor Protocol Number: 2013-001467-23 Start Date*: 2013-09-04
    Sponsor Name:Italian Sarcoma Group
    Full Title: SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORR...
    Medical condition: Metastatic or local advanced Soft tissue sarcoma, not amenable for standard chemotherapy regimen (doxorubicine/epirubicine and/or ifosfamide).
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003145-17 Sponsor Protocol Number: TH-CR-406/SARC021 Start Date*: 2012-02-28
    Sponsor Name:Threshold Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S...
    Medical condition: Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) HU (Completed) PL (Prematurely Ended) BE (Completed) IT (Completed) AT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002093-12 Sponsor Protocol Number: 1506-STBSG Start Date*: 2017-07-04
    Sponsor Name:European Organisation for Research and Treatment of
    Full Title: A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastat...
    Medical condition: Metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) NL (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003303-35 Sponsor Protocol Number: IB2019-04 Start Date*: 2021-04-08
    Sponsor Name:Institut Bergonié
    Full Title: Combining epigenetic and immune therapy to beat cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001415-29 Sponsor Protocol Number: 04-ALO-002 Start Date*: 2006-06-09
    Sponsor Name:Intercytex
    Full Title: A phase IIa uncontrolled study to evaluate hair growth in subjects with male-pattern baldness using a cell suspension of expanded autologous dermal papilla cells (ICX-TRC).
    Medical condition: Androgenetic Alopecia - Male Pattern Baldness.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000232-10 Sponsor Protocol Number: NN8640-4245 Start Date*: 2019-05-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no ca...
    Medical condition: Short stature in children born small for gestational age with no catch-up growth by 2 years of age or older
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NO (Ongoing) IE (Completed) EE (Completed) HU (Trial now transitioned) LV (Trial now transitioned) PL (Completed) ES (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024483-17 Sponsor Protocol Number: E7389-G000-309 Start Date*: 2011-06-30
    Sponsor Name:Eisai Ltd
    Full Title: A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.
    Medical condition: Soft tissue sarcoma (STS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GB (Completed) AT (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002366-13 Sponsor Protocol Number: IB2020-02 Start Date*: 2021-12-20
    Sponsor Name:Institut Bergonié
    Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas
    Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003042-16 Sponsor Protocol Number: IIBSP-PTE-2018-35 Start Date*: 2019-02-08
    Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau
    Full Title: Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane...
    Medical condition: Pterigyum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000831-34 Sponsor Protocol Number: GoforGH Start Date*: 2022-01-11
    Sponsor Name:Medical University of Vienna
    Full Title: InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000968-42 Sponsor Protocol Number: PRPZDSKIN Start Date*: 2016-06-23
    Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE
    Full Title: Study on the healing of the partial skin graft donor site in burn patients after application of platelet-rich plasma (PRP) or plasma rich in growth factors versus usual therapeutical practice.
    Medical condition: Study on healing the graft donor skin on burn patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001282-17 Sponsor Protocol Number: E7389-G000-223 Start Date*: 2018-03-23
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S...
    Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005607-13 Sponsor Protocol Number: NN8640-4467 Start Date*: 2022-07-15
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ...
    Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    23.0 100000004859 10066333 Idiopathic short stature LLT
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003504-12 Sponsor Protocol Number: GK_nilani_2012 Start Date*: 2012-10-05
    Sponsor Name:Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital
    Full Title: Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms.
    Medical condition: The catabolic effects induced by long-term glucocorticoid treatment.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 00:46:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA